[Skip to Content]
[Skip to Content Landing]
Editorial
September 13, 2000

COX-2–Selective NSAIDsNew and Improved?

Author Affiliations

Author Affiliations: Section of Gastroenterology, Boston University School of Medicine, and Boston Medical Center, Boston, Mass.

JAMA. 2000;284(10):1297-1299. doi:10.1001/jama.284.10.1297

Gastrointestinal (GI) toxicity induced by nonsteroidal anti-inflammatory drugs (NSAIDs) is among the most common serious adverse drug events in the industrialized world. Gastroduodenal ulcers can be demonstrated by endoscopy in 10% to 20% of patients who take NSAIDs on a regular basis, and the annual incidence of clinically important GI complications approaches 2%.1 The impact of NSAIDs on public health is significant and has provided the impetus to search for safer but equally effective anti-inflammatory agents.

First Page Preview View Large
First page PDF preview
First page PDF preview
×